NCT07088263View on ClinicalTrials.gov

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

July 24, 2027

Study Completion Date

June 24, 2028

Conditions
Breast Neoplasms
Interventions
DRUG

Gemcitabine, Vinorelbine, Eribulin, or Utidelone

Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.

Trial Locations (1)

510080

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER